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Abstract 
 
Aims: Advances of cardiac CT angiography (CTA) have been developed for dose reduction, 
but their efficacy in clinical practice is largely unknown. This study was designed to evaluate 
radiation dose exposure and utilization of dose-saving strategies for contrast-enhanced cardiac 
CTA in daily practice. 
Methods and Results: Sixty one hospitals from 32 countries prospectively enrolled 4502 
patients undergoing cardiac CTA during one calendar month in 2017. CTA scan data and 
images were analyzed in a central core lab and compared to a similar dose survey performed 
in 2007. Linear regression analysis was performed to identify independent predictors 
associated with dose. The most frequent indication for cardiac CTA was the evaluation of 
coronary artery disease in 89% of patients. The median dose-length-product (DLP) of 
coronary CTA was 195 mGy*cm (IQR: 110 to 338 mGy*cm). When compared with 2007, 
the DLP was reduced by 78% (p<0.001) without an increase in non-diagnostic coronary 
CTAs (1.7% in 2007 vs. 1.9% in 2017 surveys, p=0.55). A 37-fold variability in median DLP 
was observed between the hospitals with lowest and highest DLP (range of median DLP: 57 
to 2090 mGy*cm). Independent predictors for radiation dose of coronary CTA were: body 
weight, heart rate, sinus rhythm, tube voltage, iterative image reconstruction and the selection 
of scan protocols. 
Conclusion: This large international radiation dose survey demonstrates considerable 
reduction of radiation exposure in coronary CTA during the last decade. However, the large 
inter-site variability in radiation exposure underlines the need for further site-specific training 
and adaptation of contemporary cardiac scan protocols. 
 
Key words: Cardiac CT angiography, radiation dose exposure, dose-length-product, dose-
saving strategies 
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Introduction 
Cardiac computed tomography angiography (CTA) is an increasingly used noninvasive 
imaging method in cardiology.1, 2 Due to the high diagnostic accuracy, coronary CTA clarifies 
the diagnosis of angina in patients with suspected coronary artery disease (CAD) in addition 
to standard clinical care3 and coronary CTA is able to rule out CAD with high negative 
predictive value.4 The improved diagnostic capabilities may alter downstream testing and 
clinical care in a significant proportion of patients, which may reduce cardiac events.3, 5 
Finally, coronary CTA carries significant prognostic information.6 
Radiation exposure from cardiac CTA carries the potential risk of cancer induction in a dose-
dependent manner.7 Accordingly, safety considerations of cardiac CTA are an ongoing 
concern and CT imager should aim to reduce radiation dose exposure to be “as low as 
reasonably achievable” (ALARA principle), while maintaining diagnostic image quality.8 
One decade ago, the international dose survey PROTECTION I collected data from 1965 
cardiac CT studies and evaluated the radiation exposure from cardiac CTA.9 Since then, 
advances in CT technology including new acquisition techniques and software algorithms, 
have been developed and societal guidelines as well as clinical studies have advocated for a 
consequent use of these techniques to lower radiation dose.10-15 However, the utilization and 
efficacy of modern techniques for radiation dose reduction in real-world clinical practice 
across the globe is currently unknown. Thus, the current dose survey was designed to 
investigate the radiation dose of cardiac CTA, the utilization and efficacy of established dose 
saving strategies and the potential for further radiation dose reduction in a real-world setting 
in 2017. 
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Methods 
Study protocol 
The study design of the 2017 dose survey, entitled Prospective Multicenter Registry on 
RadiaTion Dose Estimates of Cardiac CT AngIOgraphy IN Daily Practice in 2017 
(PROTECTION VI), has been described previously.16 The dose survey is an international, 
industry-independent, multi-vendor, prospective, observational study. With the objective to 
garner a representative worldwide sampling, a total of 435 clinicians from 62 different 
countries were invited as identified by literature research and by membership of the Society of 
Cardiovascular Computed Tomography (SCCT). The study collaborators enrolled all 
consecutive patients undergoing cardiac CTAs during one month between March and 
December 2017. CT studies before transfemoral aortic valve replacements were excluded, due 
to necessity to image the entire aorta and the heterogeneity in acquisition protocols. Cardiac 
CTAs were carried out according to local standard of clinical care. Data was analyzed in a 
central core laboratory. Each study site consulted the responsible local ethics committee to 
evaluate the study protocol, which had to be approved prior to patient enrollment. All patients 
gave written informed consent as required at the individual study sites and data was obtained 
prospectively. An Executive Steering Committee composed of a group of physicians with 
expertise in cardiac CTA, clinical research and statistics supervised the study. The study has 
been registered with clinicaltrials.gov (NCT02996903). 
 
Strategies for Reduction of Radiation Dose 
The selection of strategies for radiation dose reduction was at the discretion of the local study 
investigators. The conventional retrospectively ECG-gated helical scan protocol is a robust 
scan technique, which is least radiation efficient. Prospectively ECG-triggered scan 
techniques, including the axial and high-pitch scan modes, deliver the radiation efficiently 
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only during a short fraction of the R-R interval and is recommended for patients with sinus 
rhythm and heart rates ≤65 beats/min.11 Reducing the tube potential from the conventionally 
used 120 kVp to 100 kVp lowers radiation exposure without compromising diagnostic image 
quality and has been recommended for patients with a body-mass-index (BMI) ≤30 kg/sqm.12 
The combination of iterative image reconstruction (IR) with reduced radiation tube currents 
has also been shown to reduce radiation exposure during coronary CTA without 
compromising diagnostic image quality.10  
 
Estimation of radiation dose 
The parameters relevant to radiation dose were obtained from the dose report generated by the 
CT system after each cardiac CTA study. The total dose-length-product (DLP), which 
includes the radiation exposure of the entire CT investigation including among others the 
localizer and timing bolus, was the main outcome measure. The DLPCTA represents the 
radiation exposure, which was delivered for the acquisition of the CT angiography only. The 
DLP equals the CT dose index (CTDIvol) multiplied by the respective scan length.  
 
Image Quality 
Diagnostic image quality of coronary CTAs was assessed by the local investigators. Non-
diagnostic image quality was defined by severe vessel blurring or vessel discontinuity 
secondary to reconstruction artifacts, which did not allow the exclusion of obstructive 
coronary lesions. Coronary CTAs were considered as non-diagnostic when at least one 
coronary artery was of non-diagnostic image quality. 
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Statistical Analysis 
Variables are expressed as counts with percentages or medians with interquartile ranges. 
Comparison of groups was performed with Wilcoxon-Mann-Whitney U-test or chi-square test 
as appropriate. Multivariable linear regression analysis with backward variable elimination 
was performed to identify predictors significantly associated with radiation dose in coronary 
CTA. A logistic regression analysis with the endpoint of performance to a diagnostic 
reference level was additionally performed. A generalized estimation equation model was 
used to account for the clustering effect of this multicenter trial. A p-value <0.05 was 
considered to be statistical significant. Statistical analysis was performed using R version 
3.4.1.  
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Results 
Patient and Study Site Characteristics 
Clinicians of 61 international sites (42 university hospitals, 19 community hospitals) from 32 
different countries participated in the study (see supplementary Table S1 for regional 
enrollment). These sites contributed 4502 patients undergoing diagnostic cardiac CTA 
(median of 51 patients per site during the month of enrollment; IQR 27 – 91 patients). The 
median site experience for the performance of cardiac CTA studies was 10.5 years (IQR 7 – 
13 years). Patient and study site characteristics of the 2017 dose survey are listed in Table 1; 
the characteristics of the 2007 dose survey are listed for comparison. In 2017, median 
patient’s age was 60 years (IQR 51 - 69 years) and their median BMI was 26.8 kg/sqm (IQR 
24.1 – 30.1 kg/sqm). Ninety percent of patients (4055 patients) were examined in sinus 
rhythm and beta blockers were administered in 66% (2973 patients) resulting in a median 
heart rate of 60 beats/min (IQR 55 – 67 beats/min).  
The main indication for cardiac CTA was the evaluation of the coronary arteries (coronary 
CTA) in 89% of patients. Planning of electrophysiologic procedures (4%) and visualization of 
bypass grafts (3%) were less frequent indications. All four major CT manufacturers were 
represented with examination of at least 13% of the enrolled patients. At the time of data 
collection modern CT scanners were used in both surveys with 96% and 91% of scans 
performed 64-slice and ≥128-slice CT scanners in the 2007 and 2017 dose surveys, 
respectively.  
 
Radiation Dose 
The median total DLP of all 4502 patients included in the 2017 dose survey was 252 
mGy*cm (IQR 154 – 412 mGy*cm). The median total DLP for coronary CTAs was 246 
mGy*cm (IQR 153 – 402 mGy*cm) with 79% of the radiation exposure resulting from the 
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coronary CTA (DLPCTA: 195 mGy*cm, IQR 110 – 338 mGy*cm, Table 2). The observed 
DLP of 195 mGy*cm corresponds to effective doses of 2.7 or 5.1 mSv, estimated using the 
thoracic or the recently published cardiac DLP to effective dose conversion factor of 0.014 or 
0.026 mSv / mGy*cm, respectively.17, 18 Compared with the 2007 survey, a significant 78% 
reduction in DLPCTA was observed in 2017 (p<0.001). The regional development of radiation 
exposure from 2007 to 2017 is presented in Table 2. Figure 1 summarizes the reduction in 
radiation dose and the variability of DLPCTA between study sites in the 2007 and 2017 dose 
surveys. While a 7-fold difference was observed in the 2007 dose survey between the study 
sites with lowest and highest median DLPCTA (lowest and highest DLPCTA in 2007: 331 and 
2146 mGy*cm, respectively), this dose variability increased to a 37-fold difference in the 
2017 dose survey (lowest and highest median DLPCTA in 2017: 57 and 2090 mGy*cm, 
respectively). DLPCTA data stratified for gender and CT manufacturer are displayed in Figure 
2 (further stratification according to CT model is given in supplementary Figure S1). 
Compared to the 2007 dose survey, the reduction in radiation dose did not increase the rate of 
non-diagnostic CTA studies in 2017. The rates of non-diagnostic coronary CTAs were 1.7% 
and 1.9% in 2007 and 2017, respectively (p=0.55). 
 
Use of Dose Saving Strategies 
The relationship between radiation tube potential and DLPCTA is displayed in Figure 3A. 
Considering the cohorts of both surveys, the use of a tube potential of ≤100 kVp increased 
significantly from 5% to 56% in the 2007 and 2017 surveys. When a BMI threshold of ≤30 
kg/sqm is considered for the eligibility of a ≤100 kVp tube potential, 6% and 70% of eligible 
patients were studied with a ≤100 kVp scan protocol in the 2007 and 2017 dose surveys, 
respectively. A tube potential of less than 100 kVp, which has not been used in 2007, was 
applied in 14% of patients in 2017.  
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In the 2007 dose survey, 94% of patients were scanned using retrospectively ECG-gated 
helical imaging and only 6% of patients were examined by prospectively ECG-triggered axial 
imaging. In the 2017 dose survey, retrospective helical imaging was decreasingly utilized in 
only 11% of patients and prospectively ECG-triggered axial scanning was favored in 78% of 
patients. ECG-triggered high-pitch helical imaging which is available on dual-source CT 
systems, was applied in 11%. Compared to retrospectively ECG-gated helical scanning, the 
prospectively ECG-triggered scan modes (axial or high-pitch) resulted in a 74% reduction in 
radiation dose in the 2017 dose survey (p<0.001; Figure 3B). IR methods, which were not 
available in 2007, were used in 83% of patients in the 2017. Application of IR techniques 
resulted in a 33% reduction of radiation dose, when compared with standard filtered back 
projection (p<0.001, Figure 3C). 
 
Predictors for Radiation Dose 
In the multivariable linear regression model, three patient-related and three scan-related 
variables of a total of 11 included parameters (see supplementary Table S2) were identified as 
independent predictors associated with radiation dose of coronary CTA. An increase in body 
weight of 10 kg, an increase in heart rate of 10 bpm and the absence of sinus rhythm were 
associated with an increase of radiation dose of 7%, 8% and 21%, respectively (all p<0.01; 
Figure 4). A decrease in the tube potential of 10 kVp and the use of IR were associated with a 
dose reduction of 21% and 30%, respectively (both p<0.01).  Finally, the use of the ECG-
gated low-pitch helical scan technique resulted in an increase of radiation dose by 313% 
(p<0.001), while the use of the ECG-triggered high-pitch scan technique was associated with 
30% dose reduction (p=0.08) when compared to the axial scan technique. The results were 
confirmed in a second logistic regression model, which addressed the performance to the 
proposed diagnostic reference level (see also discussion and supplementary Table S3). 
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Discussion 
Cardiovascular CT has become an established and increasingly used technique mainly for the 
diagnostic assessment of coronary artery disease burden in patients with chest pain. Although 
several studies have evaluated strategies to reduce the radiation exposure of cardiac CT 
imaging, there is still concern about the delivered dose in daily practice. The current 
international dose survey demonstrates that the radiation exposure associated with 
cardiovascular CT has been tremendously reduced by 78% over the last decade. This progress 
contributed to the establishment of cardiac CT as frequently used non-invasive imaging 
method supported by national guidelines.19 The determined international median DLP of 
coronary CTA corresponds to a recent national dose survey performed in the United 
Kingdom.20 The achieved dose reduction can be attributed to several important factors: (1) the 
increasing awareness about radiation safety and the growing experience and knowledge of CT 
imagers in cardiovascular CT, (2) the publication and adherence to best practice guidelines for 
cardiac CT imaging,13 and (3) the availability of scan protocols in modern CT scanners, which 
are radiation dose efficient.  
Scan protocols with a reduced tube potential and prospectively ECG-triggered scan protocols 
were, among others, the main contributor to the reduced radiation exposure in the 2017 dose 
survey. The use of 100 kVp instead of the conventional 120 kVp scan protocols in non-obese 
patients has been shown to reduce radiation exposure by 29% in a randomized comparison 
without compromising diagnostic image quality.12 Over the last decade, the frequency of use 
of ≤100 kVp scan protocols has raised by over 10-fold from 5% in 2007 to 56% in 2017. 
Similarly, the use of prospectively ECG-triggered scan modes has shown to reduce radiation 
exposure by at least 69% without compromising diagnostic image quality.11, 21 These 
prospectively triggered scan modes were applied in 89% of patients undergoing coronary 
CTA in 2017, while the frequency was only 6% in 2007.  
 11 
The observed low median DLPCTA of 195 mGy*cm for a coronary CTA corresponds to an 
effective dose estimate of 2.7 or 5.1 mSv depending on the applied conversion factor (k = 
0.014 or 0.026 mSv / mGy*cm)17, 18. The effective dose estimates of coronary CTA are 
considerably lower than the recently published median effective dose estimates of 10.0 mSv 
for myocardial perfusion imaging, obtained from a comparable worldwide dose survey.22 This 
difference may result in an improvement in population safety, if coronary CTA would be 
preferably used over myocardial perfusion imaging in patients with suspected CAD. The 
current dose survey allow for the determination of a new diagnostic reference level for 
coronary CTA. The diagnostic reference level, which is typically set at the 75th percentile 
dose level for a typical-sized patient and for a certain radiological procedure, is not the 
recommended or preferred dose, but rather an action level at which additional investigation 
into the dose used should be performed. Based on the current results, a new diagnostic 
reference level of 400 mGy*cm should be considered for coronary CTA. In 2017, median 
DLPs for coronary CTA were above this proposed diagnostic reference level in 13 of 61 
participating centers (see supplementary Figure S2). This observation but even more the 37-
fold difference in median DLPs between the study sites with the lowest and highest median 
DLPs underlines the need and potential for further education around dose reduction strategies 
and standardization of coronary CTA scan protocols. Considering the 89% use of 
prospectively ECG-triggered scan protocols (axial or high-pitch) in the current survey, a 
further increase in use will be difficult to achieve, when the presence of a stable sinus rhythm 
and a heart rate of ≤65 beats/min are respected as selection criteria. In contrast, a scan 
protocol with ≤100 kVp tube potential was selected in “only” 70% of eligible patients, if a 
conservative BMI threshold of ≤30 kg/sqm was considered as eligibility criterion. Although 
this rate increased considerably from 2007 to 2017, this also indicates, that another 30% of 
patients with a BMI of ≤30 kg/sqm would have qualified for this dose saving scan protocol. A 
tube potential of 100 kVp has been successfully applied in some studies in patients up to a 
 12 
body weight of even 100 kg without compromising image quality.23 If this body weight 
threshold would have been exploited as eligibility criterion, then even 36% of patients from 
the 2017 dose survey would have qualified for a low-dose 100 kVp scan protocol. Finally, 
scan protocols with tube potentials less than 100 kVp have demonstrated a large potential for 
further dose reductions,24 but they have been used only in 14% of patients in the current dose 
survey.  
The results of the 2017 dose survey for cardiovascular CT have relevant implications on 
different levels of our health systems: On a patient level, the radiation doses should not 
discourage patients from undergoing coronary CTAs, when clinically indicated. In fact, an 
effective dose of 5 mSv in a 60-year-old patient (median age in the current survey) adds only 
a small, negligible additional risk to life-time cancer risk, but the diagnostic information and 
the clinical consequences resulting from a coronary CTA may outweigh this very small 
theoretical additional cancer risk. This becomes even more evident when the 0.05% estimated 
risk of fatal malignancy from a 10 mSv CT scan is compared to the 50% reduction in fatal and 
nonfatal myocardial reduction observed already 3 years after a coronary CTA.5, 25 However, 
the large variability in radiation doses between participating study sites indicates that patients 
may select certified non-invasive imaging centers for their CT studies, because the likelihood 
of obtaining low-dose CT studies might be higher in certified than non-certified imaging 
centers. On a physician and institutional level, a continuous monitoring of patient’s 
radiation exposure as well as the participation in dose surveys20, 26 will allow for 
benchmarking with other physicians and institutions. The participation in such programs has 
been shown to improve “best practice” performance.26 On a societal level, the 2017 radiation 
survey reveals the importance of education. The publication of guidelines as well as the 
organization of educational sessions on radiation exposure will improve the adherence to best 
practice recommendations.27 Finally, on an industry level, the current study results claim for 
the set-up of default scan protocols, which are dose-efficient, as well as the development of 
 13 
applications supporting the automated selection of optimal low-dose scan parameters, which 
will secure low-dose cardiac imaging for the individual patient. 
Limitations 
The lack of financial support for study conduction allowed the gathering of data without bias, 
but limited also the participation of additional sites.  
 
In conclusion, the 2017 radiation dose survey demonstrates that the radiation exposure from 
cardiac CTA has been considerably reduced over the last 10 years. This was accomplished by 
an increased use of (a) low tube potential scan protocols, (b) prospectively ECG-triggered 
axial and high-pitch scan protocols, and (c) iterative image reconstruction. However, a large 
37-fold inter-site variability in median radiation dose was observed, which underlines the 
need for further site-specific training and adaptation of contemporary cardiac scan protocols. 
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Figure legends 
Figure 1: Reduction of dose-length-product from coronary CTAs and variation between 
study sites. Left: Box plots illustrate DLP of all coronary CTAs. Right: Variability of median 
DLP (± interquartile range, IQR) in the 2007 and 2017 dose surveys, respectively. 
 
Figure 2: Differences in dose-length-product of coronary CTA by gender (A) and CT 
manufacturer (B). 
 
Figure 3: Effect of dose saving strategies with tube potential reduction (A), scan mode 
(B) and application of IR (C) on dose-length-product in coronary CTA.  
 
Figure 4: Independent predictors of radiation dose from coronary CTAs. Change of 
radiation dose in coronary CTA by independent patient and scan-associated factors as 
identified by a multivariable linear regression analysis. Retrospectively ECG-gated low-pitch 
helical and prospectively ECG-triggered high-pitch helical scan modes were compared to the 
axial scan technique.  
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Table 1: Patient and study site characteristics 
 
2007 Dose Survey 
(1965 patients) 
2017 Dose Survey 
(4502 patients) 
Patient characteristics   
Age, years NA 60 (51 – 69) 
Gender: male, %(n) NA 58 (2623) 
Patient height, m 1.70 (1.63 – 1.77) 1.70 (1.60 – 1.80) 
Patient weight, kg 77 (66 – 87) 78 (67 – 90) 
BMI, kg/sqm 26.2 (23.8 – 28.8) 26.8 (24.1 – 30.1) 
Indication for cardiac CTA   
 Coronary artery evaluation, %(n) 82 (1611) 89 (4006) 
 EP planning study, %(n) 2 (38) 4 (177) 
 CABG, %(n) 12 (225) 3 (122) 
 Other, %(n)a 4 (91) 4 (197) 
ß-Blocker medication    
 None, %(n) 42 (828) 33 (1501) 
 Taking daily, %(n) 12 (233) 13 (603) 
 Administration for CTA, %(n) 46 (904) 53 (2370) 
 unknown, %(n) 0 0.6 (28) 
Sinus rhythm, %(n) 95 (1874) 90 (4055) 
Heart rate, beats/min 61 (55 – 75) 60 (55 – 67) 
   
Study site characteristics   
Site experience, years 3 (1.5 – 5.5) 10.5 (7.0 – 13.0) 
Number of cardiac CTAs/month 26 (10 – 46) 51 (27 – 93) 
CT system   
 16-slice CT, %(n) 4% (72) 0% 
 64-slice CT, %(n) 96% (1893) 9% (387) 
 ≥128-slice CT, %(n) NA 91% (4115) 
CT manufacturer   
 GE, %(n) 24 (466) 26 (1168) 
 Philips, %(n) 8 (159) 13 (574) 
 Siemens, %(n) 59 (1155) 48 (2160) 
 Toshiba, %(n) 9 (185) 13 (600) 
Values are median (interquartile range) or % (number of patients). NA, not available.  
a Other indications for cardiac CTA included among others triple-rule-out CTs, visualization of the cardiac 
anatomy and coronary anomalies. 
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Table 2: Scan characteristics for coronary CT angiographies  
 
2007 Dose Survey 
(1611 patients) 
2017 Dose Survey 
(4006 patients) 
 
P  
value 
Scan length, mm 131 (118 – 144) 137 (125 – 157) < .001 
Total DLP, mGy*cm NA 246 (153 – 402) NA 
CTDIvolCTA, mGy 54 (38 – 74) 14 (8 – 24) < .001 
DLPCTA, mGy*cm 885 (560 – 1239) 195 (110 – 338) < .001 
    
Regional DLP for coronary CTA only    
 Europe, mGy*cm 814 (537 – 1151) 176 (93 – 312) < .001 
 North America, mGy*cm 993 (292 – 1343) 199 (124 – 340) < .001 
 Latin & South America, mGy*cm 1556 (711 – 1932) 295 (189 – 624) < .001 
 Middle East, mGy*cm 1799 (1482 – 2138) 244 (132 – 400) < .001 
 East Asia & Australia, mGy*cm 940 (599 – 1130) 169 (96 – 276) < .001 
    
Dose Saving Strategies    
Tube potential ≤100kV, %(n) 5 (82) 56 (2226) < .001 
 Tube potential <100 kV, %(n) 0 (0) 14 (564) NA 
Retrospectively ECG-gated helical scan 
protocol, %(n) 
94 (1512) 11 (447) < .001 
 Subgroup with ECG-correlated 
modulation of tube current, %(n) 
95 (1440) 73 (325) < .001 
Prospectively ECG-triggered axial scan 
protocol, %(n) 
6 (99) 78 (3094) < .001 
Prospectively ECG-triggered high-pitch 
helical scan protocol, %(n) 
0 (0) 11 (449) NA 
Iterative image reconstruction, %(n) 0 (0) 83 (3306) NA 
Values are median (interquartile range) or % (number of patients).  NA, not available. 
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One-sentence summary 
The PROTECTION VI study shows a considerable reduction of radiation dose in coronary 
CT imaging by 78% during the last decade, but also demonstrates the need for further site-
specific training and adaptation of contemporary cardiac scan protocols as indicated by a 
large inter-site variability in radiation exposure. 
 
Take-home figure 
Figure 1 of the manuscript 
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